3. Jazz Pharmaceuticals ( JAZZ) is a specialty pharmaceutical company with two products: Xyrem and Luvox CR. Jazz will announce third-quarter results on Nov. 1.

For the third quarter of 2011, net income is seen increasing to $40.60 million from $17.25 million in the year-ago quarter. Earnings per share are estimated at 92 cents, up from 41 cents in the prior-year period. Sales are seen rising 61% to $72.18 million from $44.75 million in the same quarter prior year. Gross margin is likely to expand to 94.73% from 93.09% in the year-ago period.

Of the six analysts covering the stock, four recommend a buy and two suggest a hold. Analysts polled by Bloomberg expect the stock to gain almost 34.2% to $53.50 from current levels over the next 12 months.

If you liked this article you might like

Dow, S&P 500 Set New Records as Fed Moves to Unwind Balance Sheet

Stocks In Negative Territory as Chances for December Hike Surge

The Wait for 'Milestone' Fed Meeting Keeps Stocks in Flux

The 6 Medications Being Used to Tackle the Opioid Epidemic